Atrial fibrillation at discharge from the hospital in patients undergoing mitral valve repair

Thoracic and Cardiovascular Surgeon

Volumn 53, Issue 1, 2005, Pages 41-45

  Jovin, Angelika ^a,c,d   Hashim, S ^a   Jovin, I S ^b   Clancy, J F ^b   Klovekorn W P ^c   Muller Berghaus G ^c  

^a YALE NEW HAVEN HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KERCKHOFF HEART CENTER   (Germany)

^d MIDDLESEX HOSPITAL   (United States)

Author keywords

ACE inhibitors; Anticoagulants; Atrial enlargement; Atrial fibrillation; Mitral valve; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG INDICATION; DRUG USE; FEMALE; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MITRAL VALVE REPLACEMENT; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT DISCHARGE; ROC CURVE; WARFARIN;

EID: 14244266653     PISSN: 01716425     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-830460     Document Type: Article

References (20)

1. Hahn C, Vlahakes GJ. Nonreplacement operations for mitral valve regurgitation. Annu Rev Med 1997; 48: 295-306
2. The Society of Thoracic Surgeons. National Database Spring 2002 Executive Summary. www.sts.org (accessed 8.10.2002)
3. Almassi GH, Schowalter T, Nicolosi AC, Aggarwal A, Moritz TE, Henderson WG, Tarazi R, Shroyer AL, Sethi GK, Grover FL, Hammermeister KE. Atrial fibrillation after cardiac surgery: A major morbid event? Ann Surg 1997; 226: 501-513
4. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: Population based estimates. Am J Cardiol 1998; 82: 2-9
5. Benjamin E, Levy D, Varizi S, Dágostino RE, Ralph B, Belanger A, Wolf P. Independent risk factors for atrial fibrillation in a population based cohort: The Framingham Heart Study. JAMA 1994; 271: 840-844
6. Gohlke-Bärwolf C. Anticoagulation in valvar heart disease: new aspects and management during non cardiac surgery. Heart 2000; 84: 567-572
7. Obadia JF, el Farra M, Bastien OH, Lievre M, Martelloni Y, Chassignolle JF. Outcome of atrial fibrillation after mitral valve repair. J Thorac Cardiovasc Surg 1998; 115: 179-185
8. Heras M, Chesbro J, Fuster V, Penny WJ. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995; 25: 1111-1119
9. Lim E, Barlow C, Hosseinpour R, Wisbey C, Wilson K, Pidgeon W, Charman S, Barlow JB, Wells FC. Influence of atrial fibrillation on outcome following mitral valve repair. Circulation 2001; 104: 59-63
10. Vogt PR, Brunner-La Rocca HP, Rist M, Zünd G, Genoni M. Preoperative predictor of recurrent atrial fibrillation late after successful mitral valve reconstruction. Eur J Cardiothoracic Surg 1998; 13: 619-624
11. Goldsmith IR, Blann AD, Andrew D, Patel RL, Lip GY. Von Willebrand factor fibrinogen, and soluble P selectin levels after mitral valve replacement versus valve repair. Am J Cardiol 2000; 85: 1218-1288
12. Bonow RO, Carabello B, De Leon AC Jr, Edmunds LH Jr, Fedderly BJ, Freed MD, Gaasch WH, McKay CR, Nishimura RA, O'Gara PT, O'Rourke RA, Rahimtoola SH, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Gibbsons RJ, Russell RP, Ryan TJ, Smith SC Jr. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 1998; 98: 1949-1984
13. Tiede DJ, Nishimura RA, Gastineau DA, Mullany CJ, Orszulak TA, Schaff HV. Modern management of prosthetic valve anticoagulation. Mayo Clin Proc 1998; 73: 665-680
14. Armamendi JL, Agredo J, Llorente A, Larrarte C, Pijoan J. Prevention of thromboembolism with ticlopidine shortly after valve repair or replacement with a bioprosthesis. J Heart Valve Dis 1998; 7: 611-614
15. Brandt RR, Neumann T, Neuzner J, Rau M, Faude I, Hamm CW. Transcatheter closure of atrial septal defect and patent foramen ovale in adult patients using the Amplatzer occlusion device: No evidence for thrombus deposition with antiplatelet agents. J Am Soc Echocardiogr 2002; 15: 1094-1098
16. Enriquez-Sarano M, Orszulak T, Schaff HV, Abel MD, Tajik AJ, Frye RL Mitral reurgitation: A new clinical perspective. Mayo Clin Proc 1997; 72: 1034-1048
17. Pedersen OD, Bagger H, Kober L et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-380
18. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodelling in atrial fibrillation. Circulation 2000; 101: 2612-2617
19. Naccarella F, Naccarelli GV, Maranga SS, Lepera G, Grippo MC, Melandri F, Gatti M, Pazzaglia S, Spinelli G, Angelini V, Ambrosioni E, Borghi C, Giovagnorio MT, Nisam S. Do ACE inhibitors or angiotensin II antagonists reduce total mortality and arrhythmic mortality? A critical review of controlled clinical trials. Curr Opin Cardiol 2002; 17: 6-18
20. Onnasch JF, Schneider F, Mierzwa M, Mohr FW. Mitral valve repair versus mitral valve replacement. Z Kardiol 2001; 90: 75-80